Kornimate/medical-research-clean huggingface dataset:
bacterial vaginosis in pregnancy: detection by weekly vaginal ph testing

Conditions: Pregnancy; Bacterial Vaginosis; Preterm Delivery

Summary: interventional study to assess the effect of early detection and treatment of bacterial vaginosis in pregnancy on preterm delivery rate.


Eligibility criteria:
inclusion criteria: * pregnant women exclusion criteria: * diabetes mellitus (pre-gestational) * hypertension (pre-gestational) * malformations on ultrasonography at 12 weeks
etude tomos- apport de la tomosynthèse dans le bilan d'extension locorégional préthérapeutique d'une tumeur du sein : recherche de multicentricité tomos study- contribution of tomosynthesis in locoregional pretherapeutic staging of a breast tumor: multicentricity search

Conditions: Mammary Tumor

Summary: the main objective of the study is to assess the sensitivity and specificity of tomosynthesis in detecting the multicentricity of mammary tumor.

the secondaries objectives of the study are: * sensitivity and specificity in detecting multifocality of breast tumor * sensitivity and specificity of tomosynthesis in the detection of contralateral tumors * predetermination of potential targets for ultrasound

Eligibility criteria:
inclusion criteria: * age\> 18 years. * patients with a breast tumor, regardless of the stage and size * compulsory affiliation to a social security system. * obtaining informed consent in writing, signed and dated. exclusion criteria: * patients with cognitive or psychiatric disorders. * patient deprived of liberty by a court or administrative. * patients with indications against the achievement of mri, mammography and tomosynthesis * pregnant women

Keywords: tomosynthesis breast cancer specificity sensitivity to assess efficacy of tomosynthesis by evaluating its sensitivity and specificity in detecting the multicentricity of mammary tumor
efficacy and safety of act-541468 in adult subjects with insomnia disorder

Conditions: Insomnia Disorder

Summary: this study evaluates the dose response of act-541468 on the change of waso from baseline to days 1 and 2, assessed by psg.

this study consists of the following phases: screening phase; double-blind treatment phase; safety follow-up phase. safety is monitored throughout the study.

Eligibility criteria:
principal inclusion criteria: * signed informed consent prior to any study-mandated procedure. * male or female aged 18-64 years (inclusive). * women of childbearing potential must have negative pregnancy tests and use reliable methods of contraception up to 30 days after eot. * body mass index (bmi): 18.5 ≤ bmi (kg/m2) \< 32.0. * insomnia disorder according to dsm-5 criteria. * insufficient sleep quantity as collected subjectively in the sleep diary and validated objectively by polysomnography. * insomnia severity index score ≥ 15. principal exclusion criteria: * any current history of sleep disorder other than insomnia, or any lifetime history of related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement (rem) behavior disorder, or narcolepsy. * self-reported usual daytime napping ≥ 1 hour per day, and ≥ 3 days per week. * caffeine consumption ≥ 600 mg per day. * shift work within 2 weeks prior to the screening visit, or planned shift work during study. * travel ≥ 3 time zones within 1 week prior to the screening visit, or planned travel \> or= 3 time zones during study. * hematology or biochemistry test results deviating from the normal range to a clinically relevant extent as per judgment of the investigator. * ast and/or alt \> 2 × uln and/or direct bilirubin \> 1.5 × uln (except known history of gilbert's syndrome). * severe renal impairment (known or defined as estimated creatinine clearance \< 30 ml/min). * history or clinical evidence of any disease or medical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments. * any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.

Keywords: insomnia polysomnography
connect 'n unite: couples-based hiv/sti prevention for drug-involved, black msm

Conditions: HIV; Sexually Transmitted Infections

Summary: the study has the following primary aims: (1) to test whether participants assigned to cnu (a 7-session, manualized intervention entitled "connect 'n unite") engage in lower hiv/sti behavioral risk compared to participants assigned to wp (a wellness promotion attention control condition); (2) to test whether participants assigned to cnu have lower cumulative incidence of stis-chlamydia and gonorrhea-confirmed via biological assay compared to participants assigned to wp; and (3) to test whether participants assigned to cnu engage in less drug use compared to participants assigned to wp.

this study addresses the overrepresentation of the african american/black community among those living with hiv/aids in the u.s. as well as men who have sex with men (msm), the transmission category that accounts for the majority of hiv infections. in the absence of a vaccine or cure for hiv infection, behavioral risk reduction represents the best public health tool for prevention of hiv transmission. the proposed randomized clinical trial will rigorously test an innovative, couples-based intervention targeting the intersection of stimulant use and sexual risk behavior among racial/ethnic and sexual minorities, with the ultimate goal providing an evidence-based intervention that can be delivered in drug treatment and other service settings to reduce the spread of hiv among stimulant-using, african american/black msm.

Eligibility criteria:
inclusion criteria: * male * at least 18 years old * report having a "primary/main male partner" operationalized as a male with whom he has had an ongoing sexual relationship over the prior 6 months and has an emotional bond with more than any person * self-identify as african american and/or black, or identify having a main partner who self-identifies in this manner * report using a illicit use of psychostimulant and/or psychoactive drugs in the past 90 days (or has a main male partner who meets this criterion) * report having unprotected anal sex with a man who is a non-main partner in the past 90 days (or has a main male partner who meets this criterion) * identify each other as their main partner exclusion criteria: * either partner reports the occurrence of ≥1 incident of severe intimate partner violence (ipv) within the relationship in the past year as assessed using the revised conflict tactics scales * either partner has a language or cognitive impairment that prevents comprehension of study procedures as assessed during informed consent * either partner reports being currently involved (i.e., has not completed the final follow-up assessment) in an hiv prevention research study

Keywords: hiv sexually transmitted infection sti men who have sex with men msm couples african american black
lower laser therapy in orthognathics surgery

Conditions: Dentofacial Deformity

Summary: this study will examine the use of lower laser therapy to reduce edema and pain in orthognathics surgery.


Eligibility criteria:
inclusion criteria: * dentofacial deformity * healthy * mandibular surgery * no medication use

Keywords: edema pain lower laser therapy orthognathics surgery
additional effects of ujjayi pranayama

Conditions: Pulmonary Function; Coronary Artery Disease

Summary: studying the impact of ujjayi pranayama on post-coronary artery bypass grafting (cabg) patients has the potential to positively influence healthcare. this research fosters a patient-centered approach, enhancing cardio respiratory function. patient education on these practices can empower individuals, actively contributing to their recovery and overall well-being.

. exercises such as ujjayi pranayama lower heart rate and benefit high blood pressure sufferers. to determine additional effects of ujjayi pranayama on pulmonary function in post coronary artery bypass graft (cabg).

Eligibility criteria:
inclusion criteria: * participants who have 1st post op day * hemodynamically stable \& well oriented patient * extubated patient * voluntary based patients * after approval of surgeon cabg patient were recruited * tachypnea exclusion criteria: * hemodynamically unstable, * uncontrolled hypertension, * msk disease, * any previous history of tuberculosis, * neurological disease , * acute exacerbation of coad \& asthma attack, * any trauma, anxiety or rib fracture case , * during surgery complaint of graft failure , * unwilling to participate , * postural hypotension.

Keywords: ujjayi paranyama coronary artery bypass grafting pulmonary function
a randomized study of xen1101 versus placebo in focal-onset seizures (x-tole3)

Conditions: Focal Onset Seizures

Summary: the x-tole3 phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of xen1101 administered as adjunctive therapy in focal-onset seizures.

approximately 360 subjects will be randomized in a blinded manner to one of two active treatment groups or placebo in a 1:1:1 fashion (xen1101 25 mg : 15 mg : placebo). eligible subjects will have up to 9.5 weeks of baseline to assess frequency of seizures, followed by 12 weeks of blinded treatment. in order to be included in the study, subjects must be treated with a stable dose of 1 to 3 allowable antiseizure medications (asms) for at least one month prior to screening, during baseline, and throughout the double-blind treatment period (dbp) of the study. during the dbp, subjects will be instructed to orally take xen1101 or placebo once daily with an evening meal. subjects who complete the 12-week dbp will have the opportunity to qualify and enroll in a separate open-label extension (ole) study for continued treatment with xen1101. subjects who do not enroll in the ole will enter a 8-week post treatment follow-up period.

Eligibility criteria:
inclusion criteria: * be properly informed of the nature and risks of the study and give informed consent in writing, prior to entering the study * diagnosis (≥2 years) of focal epilepsy according to the international league against epilepsy (ilae) classification of epilepsy (2017). subject must have had adequate trials of at least 2 asms, which were given (and tolerated) at adequate therapeutic doses, without achieving sustained seizure freedom. * treatment with a stable dose of 1 to 3 allowable current asms for at least one month prior to screening, during baseline, and throughout the duration of the dbp * able to keep accurate seizure diaries exclusion criteria: * previously documented electroencephalogram which shows any pattern not consistent with focal etiology of seizures. * history of focal aware non-motor seizures only, non-epileptic psychogenic seizure, primary generalized seizure, developmental and epileptic encephalopathy, including lennox-gastaut syndrome. * seizures secondary to drug or alcohol use, ongoing infection, neoplasia, demyelinating disease, degenerative neurological disease, metabolic illness, progressive structural lesion, encephalopathy, or progressive central nervous system (cns) disease. * history of status epilepticus or repetitive seizures within the 12-month period preceding visit 1 where the individual seizures cannot be counted. * history of neurosurgery for seizures \<1 year prior to visit 1, or radiosurgery \<2 years prior to enrollment. * any medical condition or personal circumstance that, in the opinion of the investigator, exposes the subject to unacceptable risk by participating in the study or prevents adherence to the protocol.

Keywords: epilepsy
facial expression recognition of emotion and categorization of emotional words in gilles de la tourette's syndrome

Conditions: Gilles de la Tourette's Syndrome

Summary: gilles de la tourette's syndrome is a childhood onset inherited neuropsychiatric disorder characterised by the presence of both multiple motor tics and one or more vocal tics (noises), with psychiatric and/or behaviour disorders (such as obsessive compulsive behaviour...). this disease is associated with an dopamine system imbalance which could be responsible of a specific trouble in the recognition in some facial expression. this has been already shown in gilles de la tourette patients with obsessive compulsive behaviour. we hypothesise that patients with gilles de la tourette's syndrome present a dysfunction of voluntary and automatic treatment of emotional information. the main purpose of this study is to show if patients with gilles de la tourette's syndrome present a lack of specific facial expression recognition of emotion and determinate more precisely if this alteration involves the cortical way (high frequency way) or the under cortical way (low frequency way).

20 patients with gilles de la tourette's syndrome compared to 20 healthy paired volunteers. study progress (patients): inclusion visit : psychiatric evaluation psychological evaluation ophthalmic visit protocol : facial expression recognition test lexical decision test study progress (healthy volunteers): psychiatric evaluation ophthalmic visit facial expression recognition test lexical decision test

Eligibility criteria:
inclusion criteria: * age : \>18 years * patient with a gilles de la tourette 's syndrome such as defined in the dsmiv * stability of treatment \>1 month * mini mental state \> 26 * affiliation to social security * agreement of patients exclusion criteria: * patients with cognitive disorders, dementia, mental retardation... * patients with serious neurological pathologies * patients with a vision contrast altered. * patients who do not understand the words associated with an emotion * pregnant women * person who participate to an other study

Keywords: gilles de la tourette's syndrome facial expression recognition of emotion frequency levels automatic and voluntary information treatment patient with gilles de la tourette's syndrome
assessment of peng block as a part of multimodal analgesia following hip surgeries.

Conditions: Anesthesia

Summary: to study the effect of pericapsular nerve group (peng) block as a part of multimodal analgesia regimen for hip arthroplasties

peng block is a novel block described by giron-arango in 2018 to anesthesize the anterior hip capsule as it is supplied by branches from femoral, obturator and accessory obturator nerves, sparing motor function is an additional significance so currently the block is used to reduce post operative opioid consumption, delay time rescue analgesia, facilitate positioning for spinal anesthesia for hip surgeries and to accelerate mobility and so hospital discharge saving this vulnerable group of patient from any hospital acquired pneumonia, decreasing hospital stays, and improving recovery times would provide valuable insights into its cost-effectiveness and long-term benefits for healthcare system our primary outcome to be studied is pain assessment via numer rating scale over 24 hours postoperatively, in addition to to secondary outcomes including the aforementioned advantages.

Eligibility criteria:
inclusion criteria: * age group: 18 years and older. * asa classification i to iii. * bmi : 18-35 . * gender: both sex exclusion criteria: * patient refusal. * patients on long-term pain medications. * history of allergic reactions to local anesthetics * patients who had mental illness or uncooperative patients. * bmi \> 35 . * patients having coagulopathies or on anticoagulant or antiplatelet therapy. * severe cardiopulmonary disease * asa iv or more * diabetic or other neuropathies
double-masked study of pg324 ophthalmic solution in patients with glaucoma or ocular hypertension

Conditions: Open-angle Glaucoma; Ocular Hypertension

Summary: to evaluate ocular hypotensive efficacy and safety of pg324 ophthalmic solution compared to netarsudil (ar-13324) ophthalmic solution and latanoprost ophthalmic solution. following completion of the month 12 study visit procedures, subjects will be offered the opportunity to participate in a 2-month observational (i.e., non-interventional) trial extension.


Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. diagnosis of open angle glaucoma or ocular hypertension in both eyes 3. unmedicated intraocular pressure \>20mmhg and \<36mmhg in both eyes at 2 qualification visits. both eyes had to qualify at all qualification visits 4. corrected visual acuity equivalent to 20/200 snellen or better 5. able to give informed consent and follow study instructions exclusion criteria: 1. clinically significant ocular disease 2. pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure or narrow angles 3. unmedicated intraocular pressure ≥36mmhg 4. use of more than 2 ocular hypotensive medications within 30 days of screening 5. known hypersensitivity to any component of the formulation 6. previous glaucoma surgery or refractive surgery 7. ocular trauma within 6 months prior to screening 8. any ocular surgery or non-refractive laser treatment within 3 months prior to screening 9. recent or current ocular infection or inflammation in either eye 10. used ocular medication in either eye of any kind within 30 days of screening 11. mean central corneal thickness \>620µm at screening 12. any abnormality preventing reliable applanation tonometry of either eye 13. clinically significant abnormalities in lab tests at screening 14. clinically significant systemic disease 15. participation in any investigational study within 60 days prior to screening 16. used any systemic medication that could have a substantial effect on intraocular pressure within 30 days prior to screening 17. women who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control
special turku atherosclerosis risk factor intervention project for children (strip)

Conditions: Atherosclerosis

Summary: 1062 children at the age of 7 months and their families were randomized 1:1 in an intervention arm and a control arm. the intervention families has received child-oriented and individualized nutritional and life-style counseling that aims at decreasing child's exposure to the known environmental atherosclerosis risk factors. the controls children receive information as given at the well-baby clinics and in school health care of children and adolescents. the hypothesis is that the intervention children have healthier food habits and serum serum lipid and lipoprotein concentrations than the controls, fewer of them start smoking, and their physical activity level is higher than that of the controls.

1062 children at the age of 7 months and their families were randomized 1:1 in an intervention arm and a control arm. the intervention families has received child-oriented and individualized nutritional and life-style counseling that aims at decreasing child's exposure to the known environmental atherosclerosis risk factors. the controls children receive information as given at the well-baby clinics and in school health care of children and adolescents. the hypothesis is that the intervention children have healthier food habits and serum serum lipid and lipoprotein concentrations than the controls, fewer of them start smoking, and their physical activity level is higher than that of the controls. we further hypothesised that the life-style intervention had no adverse mental or somatic effects on the children. intima-media thickness of the carotid and brachial arterias and aorta and vasodilatation of the brachial artery induced by endogenous no production have been also been measures at 2-year intervals since the age of 11 years. recruitment to the study began in 1990 and continued for 2 years. the children are now between 14 and 16 years of age. 550 children remain in the study, which will continue until the last children have reached the age of 20 years.

Eligibility criteria:
inclusion criteria: * children at the age of 7 months and their families, recruited from the general population exclusion criteria: * severe sickness

Keywords: lipids lipoproproteins growth neurological development vascular wall blood pressure nutrient intake
are corneal epithelial defects related to changes in ocular bacterial flora in patients with anldo

Conditions: Acquired Nasolacrimal Duct Obstruction

Summary: comparison between patients with nasolacrimal duct obstruction and healthy patients and the influence of their bacterial flora on the corneal epithelium.

any patient with nasolacrimal duct obstruction above the age of 18 comparing changes in their bacterial ocular flora to healthy patients without obstruction and above 18 years of age

Eligibility criteria:
inclusion criteria: * 18 years of age or older, nasolacrimal duct obstruction exclusion criteria: * younger then 18 years of age * ocular infections * patients after repair of lacrimal duct surgery * systemic active diseases * patients taking medication that are know to influence bacterial flora of the eye
the use of flowable resin composite stent in reduction of donor site morbidity after free gingival graft harvesting

Conditions: Free Gingival Graft

Summary: after harvesting free gingival graft from the hard palate, postoperative pain as well as bleeding are the most common complications.different agents were used to protect the denuded areas on the palate as gelatin sponge, hyaluronic acid gel and platelet rich fibrin (prf) but still no gold standard material is present. pico format: p: patients with mucogingival problems in need for free gingival graft or de-epithelialized connective tissue graft.i: flowable resin composite stent. c: periodontal pack. o: post-operative pain t: day 3, 7, 14, 21 and 42 postoperative. aim of the study: to compare the effect of flowable composite stent versus periodontal pack applied to palatal donor site after free gingival graft harvesting in terms of post-operative pain reduction.

intervention: flowable resin composite stent. procedure: after the palatal sites be anaesthetized with 0.3 ml of a solution of 4% articaine and 0.001% adrenalin. graft harvesting will be performed by basic surgical techniques described by miller (1982). a rectangular shaped piece of mucosa will be harvested from the area of the hard palate by a split-thickness dissection. the graft will then be used as it on the recipient bed. the graft dimensions will be recorded (width and length). denuded palatal area will then be protected using one of the following options: 1. periodontal pack (control group) 2. flowble resin composite nexocomp flow (intervention group) postoperative instructions: postoperative instructions will include discontinuing tooth brushing and flossing around the surgical sites until the day of periodontal dressing removal (day 7). patients will be directed to consume only soft foods during the first week and to avoid any mechanical trauma. patients will be scheduled to be seen on days 7, 14, 21 and 42 periodontal pack and flowble resin composite stent will be first removed on day 7, and donor sites will be evaluated using selected parameters in both groups. thereafter, all patients will be followed up on days 14, 21 and 42 for further evaluation.

Eligibility criteria:
inclusion criteria: * patients with mucogingival defects scheduled for free gingival graft or de-epithelialized connective tissue graft. * systemically healthy exclusion criteria: * smokers * occlusal trauma at site of graft * pregnancy and lactation * patients allergic to the used agents * severe gagging reflex

Keywords: palatal donor site gingival recession periodontal diseases protective agents flowable composite